A recent study by Chen et al. (2018) found that Cys37 of SELENOW and Cys322 of tau form a disulfide bond to inhibit tau protein aggregation, indicating that SELENOW may affect tau pathology and may be associated with AD (Figure 3A). Here, MAPT is linked to Alzheimer disease.